AZD8931, an inhibitor of EGFR, ERBB2 and ERBB3 signalling, in combination with FOLFIRI: A Phase I/II study to determine the importance of schedule and activity in colorectal cancer
Latest Information Update: 14 Nov 2022
At a glance
- Drugs Sapitinib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PANTHER
- 09 Nov 2022 Results assessing the toxicity and efficacy of high-dose pulsed AZD8931 combined with chemotherapy in patients with metastatic colorectal cancer, published in the British Journal of Cancer.
- 16 Aug 2019 Status changed from active, no longer recruiting to completed.
- 08 Sep 2017 Status changed from recruiting to active, no longer recruiting.